MedTrace Logo

Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects

NCT03629067 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-01-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Pharmacokinetics and safety/tolerability between Fimasartan/Amlodipine/Hydrochlorothiazide and co administration of Fimasartan/Amlodipine and Hydrochlorothiazide in Healthy volunteers.

Conditions

  • Pharmacokinetics

Interventions

DRUG

Treatment T

Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide

DRUG

Treatment R

Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Kyung-sang Yu · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-13
Primary Completion
2018-11-29
Completion
2018-12-27

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03629067 on ClinicalTrials.gov